Please provide your email address to receive an email when new articles are posted on . Two different doses of CC-90001 vs. placebo slowed decline of percentage of predicted FVC at week 24.
In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
Please provide your email address to receive an email when new articles are posted on . Adverse events reported with ENV-101 have been seen with other hedgehog inhibitors. Another trial is already ...
The oral respiratory syncytial virus (RSV) fusion protein inhibitor AK0529 was found to be well tolerated and reduced viral load in infants. Both viral load and Wang Respiratory Scores improved after ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...
(MENAFN- EIN Presswire) EINPresswire/ -- The respiratory syncytial virus (RSV) fusion inhibitors market is experiencing significant momentum as advancements in healthcare and increasing respiratory ...
Proton pump inhibitors (PPIs) were strongly linked with serious infection risk among infants and young children in a large national study, suggesting caution in prescribing. In more than one million ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...
In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback